Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.

Ouédraogo A, Tiono AB, Kargougou D, Yaro JB, Ouédraogo E, Kaboré Y, Kangoye D, Bougouma EC, Gansane A, Henri N, Diarra A, Sanon S, Soulama I, Konate AT, Watson NL, Brown V, Hendriks J, Pau MG, Versteege I, Wiesken E, Sadoff J, Nebie I, Sirima SB.

PLoS One. 2013 Nov 11;8(11):e78679. doi: 10.1371/journal.pone.0078679. eCollection 2013.

2.

A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines.

Kostense S, Mommaas B, Hendriks J, Verhoeven M, Ter Haak M, Tirion F, Wiesken E, Pau MG, Radosevic K, Goudsmit J.

Clin Vaccine Immunol. 2011 May;18(5):776-82. doi: 10.1128/CVI.00547-10. Epub 2011 Mar 16.

Supplemental Content

Loading ...
Support Center